TEVA PHARMACEUTICAL INDUSTRIES LIMITED Foreign Income Tax Expense (Benefit), Continuing Operations
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) reported Foreign Income Tax Expense (Benefit), Continuing Operations of -$386.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-02-03
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED foreign income tax expense (benefit), continuing operations for fiscal 2025 was -$386.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED foreign income tax expense (benefit), continuing operations for fiscal 2024 was -$45.00M, a 111.39% decline from fiscal 2023.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED foreign income tax expense (benefit), continuing operations for fiscal 2023 was $395.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED foreign income tax expense (benefit), continuing operations for fiscal 2022 was -$676.00M, a 877.01% decline from fiscal 2021.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$386.00M 10-K · filed 2026-02-03 | |
| 2024-12-31 | -$45.00M 10-K · filed 2026-02-03 | |
| 2023-12-31 | $395.00M 10-K · filed 2026-02-03 | |
| 2022-12-31 | -$676.00M 10-K · filed 2025-02-05 | -$671.00M 10-K · filed 2023-02-10 |
| 2021-12-31 | $87.00M 10-K · filed 2024-02-12 | |
| 2020-12-31 | -$228.00M 10-K · filed 2023-02-10 | |
| 2019-12-31 | -$385.00M 10-K · filed 2022-02-09 | |
| 2018-12-31 | -$326.00M 10-K · filed 2021-02-10 | |
| 2017-12-31 | -$2.03B 10-K · filed 2020-02-21 | |
| 2016-12-31 | $312.00M 10-K · filed 2019-02-19 | |
| 2015-12-31 | $485.00M 10-K · filed 2018-02-12 | |
| 2014-12-31 | $444.00M 20-F · filed 2017-02-15 | |
| 2013-12-31 | -$240.00M 20-F · filed 2016-02-11 | |
| 2012-12-31 | -$142.00M 20-F · filed 2015-02-09 | |
| 2011-12-31 | $56.00M 20-F · filed 2014-02-10 | |
| 2010-12-31 | $144.00M 20-F · filed 2013-02-12 | |
| 2009-12-31 | $118.00M 20-F · filed 2012-02-17 | |
| 2008-12-31 | $39.00M 20-F · filed 2011-02-15 |